Signatera, a “tumor-informed” blood test developed by Natera, can detect circulating tumor DNA in the bloodstream for certain types of cancers.
“What makes the tumor DNA different is that it has certain mutations that actually lead to the uncontrolled cell growth that became the cancer,” Solomon Moshkevich, the general manager of oncology at Natera, told “Good Morning America.” “And by virtue of analyzing a sample of the tumor, from the patient, we actually know what the mutations are in that cancer and we know exactly what we’re looking for when we go analyzing the blood sample.”
The blood test works by looking at over 20,000 genes from the patient’s tumor and comparing it to normal genes. Once a unique fingerprint of that tumor is identified, a personalized blood test is created that is unique to that person’s cancer.
Signatera, which works best for solid cancers such as lung, colon, bladder and breast cancer, has proven to detect disease recurrence of some cancers at the microscopic level as much as two years earlier than a scan, according to the company.
“Having that inside information, that huge heads up, can be the difference between life and death,” said Dr. Kristi Funk, a breast cancer surgeon and the medical director for Pink Lotus, a leader in breast health and cancer care.
Funk said her patients have been using the test for the past six months, including Mariel Leibowitz, who was diagnosed with triple negative breast cancer at 32 and underwent a double mastectomy in 2019.